Coherus BioSciences Announces New Employment Inducement Grants
Coherus BioSciences (Nasdaq: CHRS) announced the grant of stock options for an aggregate of 234,000 shares to 22 new employees, effective August 24, 2022. The options have a per-share exercise price of $12.90, matching the closing trading price on the grant date. This action is part of the Company’s 2016 Employment Commencement Incentive Plan aimed at attracting new talent.
- Granting stock options shows Coherus's commitment to attracting new talent.
- Stock options offered at market price of $12.90 may incentivize employee performance.
- None.
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares of the common stock of the Company to 22 newly hired employees with a per share exercise price of
The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement Incentive Plan, which was approved by the Company’s board of directors in June 2016 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the Company.
Coherus BioSciences Contact Information:
IR Contact
Marek Ciszewski
Coherus BioSciences, Inc.
IR@coherus.com
FAQ
What stock options were granted by Coherus BioSciences?
What is the exercise price for the stock options granted by Coherus?
When did Coherus BioSciences announce the stock option grant?
Which plan facilitated the stock option grant by Coherus BioSciences?
